Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

50 trials 29 recruiting Academic / non-commercial Merged from 2 name variants

Filter these 50 trials by condition, phase, country and more.

Open in Search →

50 Registered trials

29 Recruiting

15 Completed trials

12 Countries active

84 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase III: 8 Phase II/III: 6 Phase II: 22 Phase I/II: 4 Phase IV: 4 Phase I: 1 Phase I (Other): 4 Phase I (FiH): 1

Oversight events:

5 serious breaches 1 temporary halt 2 corrective measures across 6 trials

View oversight register →

100%

15 of 15 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Colorectal cancer metastatic 2 HER2 positive breast cancer 2 Triple negative breast cancer 1 Breast cancer metastatic 1 EGFR gene mutation 1 Prostate cancer 1 Colorectal cancer 1 Pleural mesothelioma malignant recurrent 1 Clear cell renal cell carcinoma 1

Top IMPs

NIVOLUMAB 10 IPILIMUMAB 8 ATEZOLIZUMAB 5 PEMBROLIZUMAB 5 CAPECITABINE 4 PACLITAXEL 4 BEVACIZUMAB 3 CARBOPLATIN 3 CISPLATIN 3 OLAPARIB 3 OXALIPLATIN 3 3-(4-METHYLPIPERAZINE-1-CARBONYL)-7-OXABICLO[2.2.1]HEPTANE-2-CARBOXYLIC ACID 2

All trials — page 3

50 total

Sarcomas and DDR-Inhibition; a neoadjuvant phase I combined modality study - SADDRIN-1 Ended

2024-514907-32-00 Phase I (Other) 1 country
Tolerability of concurrent EBRT + Lu-PSMA for node-positive prostate cancer (PROQURE-1) Ended

2024-514168-15-00 Phase I (Other) 1 country

Showing 49–50 of 50 trials

← All sponsors A–Z